Abacavir Hypersensitivity Reaction Reporting Rates During a Decade of HLA‐B*5701 Screening as a Risk‐Mitigation Measure

INTRODUCTION: Human leukocyte antigen (HLA)‐B*5701 screening identifies patients at increased risk for abacavir (ABC) hypersensitivity reaction (HSR). Screening was adopted in GlaxoSmithKline and ViiV Healthcare clinical trials in 2007 and human immunodeficiency virus treatment guidelines in 2008. C...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Pharmacotherapy
Glavni autori: Stainsby, Chris M., Perger, Teodora M., Vannappagari, Vani, Mounzer, Karam C., Hsu, Ricky K., Henegar, Cassidy E., Oyee, James, Urbaityte, Rimgaile, Lane, Charlotte E., Carter, Lindsay M., Pakes, Gary E., Shaefer, Mark S.
Format: Artigo
Jezik:Inglês
Izdano: John Wiley and Sons Inc. 2018
Teme:
Original Research Articles
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6590466/
https://ncbi.nlm.nih.gov/pubmed/30414209
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/phar.2196
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items